Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance 24% Improvement Relative Risk Median time to PCR- 50% c19hcq.org Chen et al. HCQ for COVID-19 RCT LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? RCT 33 patients in Taiwan Trial underpowered to detect differences Chen et al., PLoS ONE, doi:10.1371/journal.pone.0242763 Favors HCQ Favors control
A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)
Chen et al., PLoS ONE, doi:10.1371/journal.pone.0242763
Chen et al., A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of.., PLoS ONE, doi:10.1371/journal.pone.0242763
Jul 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
2 very small studies with hospitalized patients in Taiwan.
RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC, p=0.4. Risk of PCR+ at day 14, RR 0.76, p = 0.71.
This paper also reports on a small retrospective study with 12 of 28 HCQ patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29, p = 0.7.
Although the viral clearance result is not statistically significant, it is consistent with the significant 20% improved viral clearance [10‑29%] from meta analysis of the 42 viral clearance results to date.
risk of no viral clearance, 24.0% lower, RR 0.76, p = 0.71, treatment 4 of 21 (19.0%), control 3 of 12 (25.0%), NNT 17, day 14.
median time to PCR-, 50.0% lower, relative time 0.50, p = 0.40, treatment 21, control 12.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chen et al., 10 Jul 2020, Randomized Controlled Trial, Taiwan, peer-reviewed, 19 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: PLOS ONE RESEARCH ARTICLE A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Chen C-P, Lin Y-C, Chen T-C, Tseng T-Y, Wong H-L, Kuo C-Y, et al. (2020) A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID19). PLoS ONE 15(12): e0242763. https://doi.org/ 10.1371/journal.pone.0242763 Editor: Stephen L. Atkin, Weill Cornell Medical College Qatar, QATAR Received: July 1, 2020 Accepted: November 9, 2020 Cheng-Pin Chen1,2☯, Yi-Chun Lin1,3☯, Tsung-Chia Chen4, Ting-Yu Tseng4, Hon-Lai Wong5, Cheng-Yu Kuo6, Wu-Pu Lin7, Sz-Rung Huang8, Wei-Yao Wang9, Jia-Hung Liao10, ChungShin Liao11, Yuan-Pin Hung12, Tse-Hung Lin13, Tz-Yan Chang13, Chin-Fu Hsiao14, YiWen Huang ID13,15, Wei-Sheng Chung4,16,17, Chien-Yu Cheng1,18, Shu-Hsing Cheng ID1,19*, on behalf of the Taiwan HCQ Study Group¶ 1 Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, 2 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, 3 Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan, 4 Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan, 5 Department of Internal Medicine, Keelung Hospital, Ministry of Health and Welfare, Keelung City, Taiwan, 6 Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare, Pingtung, Taiwan, 7 Department of Internal Medicine, Taipei Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan, 8 Department of Internal Medicine, Miaoli General Hospital, Ministry of Health and Welfare, Miaoli, Taiwan, 9 Department of Internal Medicine, Feng Yuan Hospital, Ministry of Health and Welfare, Taichung, Taiwan, 10 Department of Internal Medicine, Nantou Hospital, Ministry of Health and Welfare, Nantou, Taiwan, 11 Department of Internal Medicine, Chia Yi Hospital, Ministry of Health and Welfare, Chiayi, Taiwan, 12 Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan City, Taiwan, 13 Department of Internal Medicine, Chang Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan, 14 Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan, 15 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, 16 Department of Health Service Administration, China Medical University, Taichung, Taiwan, 17 Department of Healthcare Administration, Central Taiwan University of Science and Technology, Taichung, Taiwan, 18 School of Public Health, National Yang-Ming University, Taipei, Taiwan, 19 School of Public Health, Taipei Medical University, Taipei, Taiwan ☯ These authors contributed equally to this work. ¶ Membership of the Taiwan HCQ Study Group is listed in the Acknowledgments. * shcheng@mail.tygh.gov.tw Published: December 2, 2020 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit